- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00384839
Vidaza to Restore Hormone Thx Prostate
Phase II Study for the Use of Vidaza™ to Restore Responsiveness of Patients' Prostate Cancers to Hormonal Therapy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Colorado
-
Denver, Colorado, United States, 80218
- Rocky Mountain Cancer Center-Midtown
-
-
Florida
-
Ocoee, Florida, United States, 34761
- Cancer Centers of Florida, P.A.
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55404
- Minnesota Oncology Hematology, P.A.
-
-
Nevada
-
Las Vegas, Nevada, United States, 89109
- Comprehensive Cancer Centers of Nevada
-
-
New York
-
Albany, New York, United States, 12208
- New York Oncology Hematology, P.C.
-
-
North Carolina
-
Cary, North Carolina, United States, 27511
- Raleigh Hematology Oncology Associates
-
Hickory, North Carolina, United States, 28602
- Northwestern Carolina Oncology Hematology
-
-
Texas
-
Dallas, Texas, United States, 75246
- Texas Oncology, P.A.
-
Fort Worth, Texas, United States, 76104
- Texas Oncology, P.A.
-
Tyler, Texas, United States, 75702
- Tyler Cancer Center
-
Webster, Texas, United States, 77598
- Deke Slayton Cancer Center
-
-
Virginia
-
Norfolk, Virginia, United States, 23502
- Virginia Oncology Associates
-
-
Washington
-
Spokane, Washington, United States, 99202
- Cancer Care Nrothwest-South
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
INCLUSION CRITERIA:
- A diagnosis of histologically confirmed, progressive, advanced metastatic, or nonmetastatic prostate cancer with documented PSA progression, with a calculated PSA doubling time <3 months, on complete androgen ablation therapy. PSA progression, with or without clinical progression (symptomatic/radiologic as per RECIST) is required; measurable disease is not required.
Baseline PSA values must be followed by 2 serial increases at least 2 weeks apart (no upper limit for time for these 2 samples). Calculated PSA doubling time, for the above PSA values must be <3 months. An automated PSA doubling time calculator may be found at www.mskcc.org/mskcc/html/10088.cfm (see study tools).
- Currently on complete androgen ablation hormone therapy (an LHRH agonist plus an antiandrogen) with testosterone level <50ng/dL). Patients who are on LHRH agonist or other antiandrogenic therapy at entry will continue that therapy while on this study. Anti-androgen withdrawal is not necessary and is precluded before enrollment on the trial. The details of that therapy must be recorded in the CRF. Patients who have had an orchiectomy and who are on antiandrogen therapy are permitted on study.
- An elevated PSA level for patients progressing by PSA criteria is required (see protocol for specific detail).
- Has a Karnofsky Performance Status >70
- Is greater than 18 years of age
- Must meet specific lab values for the following criteria: granulocyte, platelet count, total bilirubin, AST and ALT, serum creatinine, calculated creatinine clearance & urinalysis (see protocol for specific detail).
- If fertile, the patient has agreed to use an acceptable method of birth control to avoid fathering a child for the duration of the study and for a period of 2 months thereafter.
- Has signed a Patient Informed Consent Form
- Has signed a Patient Authorization Form
EXCLUSION CRITERIA:
- Has only clinical progression without evidence of PSA progression
- Has received prior chemotherapy
- Has had prior treatment with Vidaza
- Has a history of hypersensitivity to any component of Vidaza (mannitol)
- Has a history of New York Heart Association (NYHA) heart disease Class III or IV (Appendix III) or myocardial infarction within 6 months prior to Day 1 or unstable arrhythmia or evidence of ischemia on electrocardiogram (ECG)
- Is receiving concurrent immunotherapy
- Is receiving concurrent bisphosphonate therapy; long-standing bisphosphonate therapy (initiated >8 weeks prior to registration) is acceptable. Bisphosphonates started within the prior 8 weeks will not be allowed since this may affect other study endpoints and render their interpretation difficult.
- Has received treatment with radiation therapy, surgery, chemotherapy, ketoconazole, corticosteroids, or an investigational agent within 1 month prior to registration, (6 weeks for radiation therapy, nitrosureas or Mitomycin C)
- Has evidence of central nervous system (CNS) involvement
- Has a serious uncontrolled intercurrent medical or psychiatric illness, including serious infection that requires systemic therapy
- Has a serious uncontrolled nonmalignant disease (liver failure, or other condition) that could compromise protocol objectives in the opinion of the Investigator
- Has a history of other malignancy within the last 5 years (except cured basal cell carcinoma of skin), which could affect the diagnosis or assessment of any of the study drugs
- Is known to be positive for the human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
- Is unable to comply with requirements of study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
azacitidine for injectable suspension
|
Vidaza: 75 mg/m2 for 5 consecutive days (Days 1-5) of each 28 day cycle.
A cycle will equal to 28 days.
Patient will receive a maximum of 12 cycles.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Patients With PSA Doubling Time >=3 Months.
Time Frame: Until progression or up to a maximum of 12 cycles
|
To determine if Vidaza can convert hormone-refractory prostate cancer to a hormone-responsive state.
This will be assessed by the proportion of patients who have a documented prostate specific antigen (PSA) doubling time >3= months.
|
Until progression or up to a maximum of 12 cycles
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PSA Response Rate
Time Frame: Every 8 weeks for 1 year.
|
Complete PSA Response defined as complete normalization of PSA maintained for at least 4 weeks, and partial PSA response defined as a decrease in PSA level of at least 50% from baseline level maintained for at least 4 weeks.
|
Every 8 weeks for 1 year.
|
Objective Response Rate by Recist (ORR)
Time Frame: Every 8 weeks for 1 year.
|
ORR = Complete Response (CR) + Parcial response (PR).
CR: Disappearance of all target lesions.
PR: At least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LD.
|
Every 8 weeks for 1 year.
|
Progression-free Survival
Time Frame: Up to 1.5 year.
|
PFS is measured from the date of randomization to the date of first documented disease progression or date of death, whichever comes first. If a patient neither progresses nor dies, this patient will be censored at last contact date. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. |
Up to 1.5 year.
|
1-year Overall Survival (OS)
Time Frame: Up to 1 year.
|
OS is measured from the date of randomization to the date of death for a dead patient.
If a patient is still alive or is lost to follow up, the patient will be censored at the last contact date.
|
Up to 1 year.
|
Changes in Fetal Hemoglobin (HbF) With Time.
Time Frame: Up to 1 year.
|
Time from baseline to maximal fetal hemoglobin (HbF).
|
Up to 1 year.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Guru Sonpavde, MD, US Oncology Research
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 05015
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer
-
Roswell Park Cancer InstituteRecruitingObesity | Overweight | Cancer Survivor | Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage A Prostate Cancer | Stage... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Regeneron Pharmaceuticals; Prostate Cancer FoundationWithdrawnStage III Prostate Cancer | Stage IV Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage IIIA Prostate Cancer | Stage IIIB Prostate Cancer | Stage IIIC Prostate Cancer
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI); SanofiTerminatedDiarrhea | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ryan Kohlbrenner, MDRadiological Society of North AmericaCompletedProstate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage...United States
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.TerminatedRandomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer (PSMA-dRT)Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate...United States
-
Ohio State University Comprehensive Cancer CenterRiverside Methodist HospitalCompletedStage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
University of California, IrvineCompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
NRG OncologyNational Cancer Institute (NCI)RecruitingProstate Adenocarcinoma | Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer... and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnStage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate...United States
Clinical Trials on azacitidine for injectable suspension
-
Point BiomedicalCompletedCoronary Artery DiseaseUnited States
-
Point BiomedicalTerminatedCoronary Artery Disease | HealthyUnited States
-
Point BiomedicalCompletedCoronary Artery DiseaseUnited States
-
Point BiomedicalCompletedCoronary Artery DiseaseUnited States
-
Point BiomedicalTerminatedCoronary Artery DiseaseUnited States
-
Point BiomedicalCompletedCoronary Artery Disease | HealthyUnited States
-
Lantheus Medical ImagingCompletedVentricular Ejection FractionUnited States
-
NantBioScience, Inc.WithdrawnNeoplastic DiseaseUnited States
-
Zafgen, Inc.CompletedObesity | Prader-Willi Syndrome | Over-weightUnited States
-
GE HealthcareICON Clinical ResearchCompletedPulmonary HypertensionUnited States